Despite the role of aerobic glycolysis in cancer, recent studies highlight the importance of the mitochondria and biosynthetic pathways as well. PPARg coactivator 1a (PGC1a) is a key transcriptional regulator of several metabolic pathways including oxidative metabolism and lipogenesis. Initial studies suggested that PGC1a expression is reduced in tumors compared with adjacent normal tissue. Paradoxically, other studies show that PGC1a is associated with cancer cell proliferation. Therefore, the role of PGC1a in cancer and especially carcinogenesis is unclear. Using Pgc1a À/À and Pgc1a þ/þ mice, we show that loss of PGC1a protects mice from azoxymethane-induced colon carcinogenesis. Similarly, diethylnitrosamine-induced liver carcinogenesis is reduced in Pgc1a À/À mice as compared with Pgc1a þ/þ mice. Xenograft studies using gain and loss of PGC1a expression showed that PGC1a also promotes tumor growth. Interestingly, while PGC1a induced oxidative phosphorylation and tricarboxylic acid cycle gene expression, we also observed an increase in the expression of two genes required for de novo fatty acid synthesis, ACC and FASN. In addition, SLC25A1 and ACLY, which are required for the conversion of glucose into acetyl-CoA for fatty acid synthesis, were also increased by PGC1a, thus linking the oxidative and lipogenic functions of PGC1a. Indeed, using stable 13 C isotope tracer analysis, we show that PGC1a increased de novo lipogenesis. Importantly, inhibition of fatty acid synthesis blunted these progrowth effects of PGC1a. In conclusion, these studies show for the first time that loss of PGC1a protects against carcinogenesis and that PGC1a coordinately regulates mitochondrial and fatty acid metabolism to promote tumor growth. Cancer Res; 71(21); 6888-98. Ó2011 AACR.
Introduction
Pioneering work by Warburg described the ability of tumor cells to use glycolysis to generate ATP and lactic acid, even in the presence of oxygen, that is, aerobic glycolysis, or as it is commonly called, the Warburg Effect (1). However, increased glucose utilization cannot be explained solely by increased ATP production as initially proposed by Warburg. Besides the generation of ATP, there are a number of other benefits of increased glucose metabolism. Glucose serves as a precursor for biosynthesis of molecules involved in generating biomass such as nucleic acids and lipids. Indeed, increased nucleic acid and lipid synthesis play an important role in many cancers (2) (3) (4) . Therefore, the ability of cancer cells to coordinate glucose metabolism is a crucial aspect of the metabolic phenotype. This has prompted interest into understanding and targeting key molecules regulating glucose metabolism.
PPARg coactivator 1a (PGC1a) is a major regulator of several key metabolic pathways. PGC1a was initially identified as the key factor driving thermogenesis in brown fat (5) . Numerous studies have since shown a key role for PGC1a in inducing the expression of genes of oxidative phosphorylation and the tricarboxylic acid (TCA) cycle in various tissues (6) (7) (8) . PGC1a also plays an important role in regulating other metabolic pathways. Recent studies show that PGC1 also promotes anabolic pathways such as de novo lipogenesis (9, 10) . This is accompanied by an increase in the pentose phosphate pathway to generate NADPH for fatty acid synthesis (9) . This highlights the important role that PGC1a plays in regulating multiple aspects of metabolism in addition to its ability to promote oxidative metabolism.
Initial studies on the role of PGC1a in cancer showed an association between reduced expression of PGC1a compared with normal adjacent tissue (11) . The ability of PGC1 to drive mitochondrial function led to speculation that reduced PGC1a in tumors may be responsible for the Warburg effect. Indeed, several studies showed that decreased PGC1a expression was associated with reduction in mitochondrial function and increased growth (12, 13) . Although the Warburg effect is a well-described phenomenon, more recent studies show that mitochondrial function is required for transformation and tumor growth (14) (15) (16) . This supports several studies suggesting a potential procancer role for PGC1a (17) (18) (19) . These studies highlight the conflicting data about the role of PGC1a in maintaining tumor growth. Regardless of the associations between PGC1 expression and established tumors or cell lines, whether or not PGC1a is involved in tumorigenesis is not known. Therefore, we have taken an approach using gain and loss of PGC1a expression to determine the role of PGC1a on tumorigenesis and tumor growth.
Materials and Methods

Animal studies
Protocols were approved by the University of Maryland Animal Care and Use Committee and conducted under veterinary supervision. PGC1a knockout (Pgc1a Colons and livers were removed from mice, and RNA was isolated using TRIzol as previously described (21, 22) . Colon carcinogenesis was induced by injecting mice once per week with 10 mg/kg azoxymethane for 8 weeks as previously described (23) . Mice were monitored for 25 weeks and then euthanized. Colons were removed and fixed for tumor analysis. For liver carcinogenesis, mice were injected at 14 days of age with 25 mg/kg diethylnitrosamine. Mice were followed up to 24 or 40 weeks and then euthanized. Livers were removed for tumor analysis. Formalin-fixed liver tissue was paraffin embedded and 5 mm sections cut by the University of Maryland Greenebaum Center Pathology Core. Liver sections from mice euthanized at 24 weeks were stained with hematoxylin and eosin and pathologic analysis and tumor number determined blindly by a board certified pathologist (W. Twaddel). For liver sections from mice euthanized at 40 weeks, due to greater tumor formation in the Pgc1a þ/þ mice, it was not possible to count individual tumors, as tumors grew into each other. Therefore, tumor burden was determined by measuring tumor area. Colons were examined blinded under a dissecting scope, and gross tumor number was determined. For xenograft studies, 1 Â 10 6 cells were injected subcutaneously into the flank of severe-combined immunodeficient (SCID) mice (Taconic) in 100 mL of media. Tumor growth was monitored every 3 days using a digital caliper and volume calculated as previously described (22) . At the end of the experiment, mice were euthanized, tumors harvested and processed for RNA, protein, and histopathology. Data were obtained from 8 to 12 mice per experimental group and experiments repeated at least 2 times. For studies inhibiting fatty acid synthesis, HT29 pcDNA control and pcDNA PGC1a expressing cells were inoculated into the flanks of SCID mice. As soon as tumors were palpable, mice were administered 10 mg/kg C75 (Toronto Chemical Company) twice a week and tumor growth monitored. Five mice per group were used for these experiments. For XCT790 inverse estrogen-related receptor (ERR) a agonist experiments, wild-type mice were treated with 25 mg/kg for 3 days by intraperitoneal injection. Livers were removed, RNA extracted, and real-time PCR carried out as described below. 
Western blotting
Tissues and cells were lysed in RIPA buffer and proteins harvested. Hundred micrograms of protein was separated using SDS-PAGE and transferred to nitrocellulose. Membranes were incubated with PGC1a (Calbiochem), SREBP1c (BD Bioscience), and actin (Sigma) antibodies and secondary anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch). Proteins were visualized using enhanced chemiluminescence.
Cell growth studies
Cells were plated at 10,000 cells per well in a 6-well plate, and cells were counted every 2 days using a hemocytometer and trypan blue exclusion as previously described (22) .
Real-time PCR
RNA was extracted from cells and tissues using TRIzol as previously described (21, 22) . cDNA was synthesized and realtime RT-PCR conducted using SYBR Green as previously described using gene-specific primers (Supplementary Table  SI ) and normalized to actin as a control (21, 22) .
Analysis of lipid metabolism
For total triacylglycerol (TAG) determination and TAG synthesis, the lipids were extracted by the Folch method from individual liver and tumor tissues. Total upper phase was dried down, resuspended in isopropanol, and assayed with triglyceride kit (Sigma) by the University of Maryland Nutrition and Obesity Research Core. Equivalent of 5 mg for liver tissue and 1 mg for tumor tissue were analyzed with thin layer chromatography extractions. Tissue lipids were separated with chloroform/acetone/acetic acid (96:4:1) as solvent. The lipids were visualized with phosphomolybdenum vapor.
For metabolic flux analysis, we used stable isotope-based tracer analysis. [U6- 13 C 6 ]glucose (>99% purity and 99% isotope enrichment for each carbon position; Cambridge Isotope Labs) was used as a tracer. Mice with HT29 pmscv and HT29 PGC1a expressing xenografts were administered 13 C glucose, and tumors and plasma were collected 3 hours later. Specific extractions and analysis were conducted as previously described and below (10, 24, 25) . Fatty acids were extracted by saponification of TRIzol cell extracts after removal of the RNA containing supernatant with 30% KOH and 100% ethanol using petroleum ether. Fatty acids were then converted to their methylated derivatives using 0.5 N methanolic HCl. Palmitate was monitored at m/z of 270. The enrichment of acetyl units and the synthesis of new lipid fraction were determined using the mass isotopomers of palmitate with the enrichment of 13 Clabeled acetyl units used to reflect synthesis of the new lipid fraction as determined by mass isotopomer distribution analysis (MIDA). Media C 13 /C 12 ratios in released CO 2 were used as the direct measure of glucose oxidation.
Gas chromatography/mass spectrometry. Mass spectral data were obtained on the HP5973 mass selective detector connected to an HP6890 gas chromatograph. The settings are as follows: gas chromatography (GC) inlet, 230 C; transfer line, 280 C; mass spectrometry (MS) source, 230 C; and MS Quad, 150
C. An HP-5 capillary column (30 m length, 250 mm diameter, 0.25 mm film thickness) was used for glucose, ribose, and lactate analysis. A Bpx70 column (25 m length, 220 mm diameter, 0.25 mm film thickness; SGE Incorporated) was used for fatty acid analysis with specific temperature programming for each compound studied as previously described.
Statistical analysis
For growth and gene expression analysis, the Student t test was used to determine statistical significance. The Fisher exact test was applied to colon cancer incidence with significance defined as P < 0.05.
Results
Loss of PGC1 protects against tumorigenesis
One of the first studies to show an association between PGC1a and cancer showed that PGC1a levels are reduced in colon-derived tumor tissue compared with normal adjacent tissue (11) . PGC1a is abundantly expressed throughout the small intestine and colon and in the stem cell crypt compartment and at the top of intestinal crypts (26) . Therefore initially, we examined the role of PGC1a in colon tumorigenesis. Mitochondrial gene targets of PGC-1a involved in the TCA cycle and oxidative phosphorylation were downregulated from the colons of PGC1a À/À mice compared with Pgc1a þ/þ mice (Fig. 1A) . We also examined whether there was a compensatory increase in PGC1b due to loss of PGC1a but found a decrease in expression ( Supplementary Fig. S1A ). We then induced tumorigenesis using a colon-specific carcinogen, azoxymethane. Azoxymethane-induced tumors originate from epithelial cells lining the colon and grow as polyps or adenomas which are similar to colon carcinoma in humans. Mice were examined for colorectal tumors 25 weeks following the last azoxymethane injection. Despite the reduction in oxidative phosphorylation 
gene expression in the Pgc1a
À/À mice, there was a significant reduction in tumor incidence in the Pgc1a À/À mice. Eightyseven percent of Pgc1a þ/þ mice had colonic polyps, whereas less than 30% of the Pgc1a À/À mice had polyps ( Fig. 1B , P < 0.01). In addition, in mice with tumors, loss of PGC1a reduced tumor multiplicity by more than 50% (Fig. 1C) . Therefore, despite studies showing reduced PGC1a expression in colon-derived tumors compared with normal tissue, loss of PGC1a protects against colon tumorigenesis. Next, we wanted to determine whether the ability of PGC1a to promote tumorigenesis was specific for the colon. PGC1a plays a key role in regulating glucose homeostasis in the liver and represents one of the most well-studied sites of action of PGC1a (7). Initially we examined the livers of Pgc1a þ/þ and Pgc1a À/À mice for the expression of PGC1a targets. Similar to previous studies, loss of PGC1a was associated with a reduction in the expression of oxidative phosphorylation and TCA cycle genes ( Fig. 2A; ref. 8 ). We also observed a decrease in PGC1b; however, it was not statistically significant (Supplementary Fig. S1B ). Next, we examined the role of Pgc1a on liver tumorigenesis using Pgc1a þ/þ and Pgc1a À/À mice. Liver carcinogenesis was induced in 14-day-old mice using the liverspecific carcinogen, diethylnitrosamine. Diethylnitrosamine is a DNA-alkylating agent that induces pericentral foci and small dysplastic hepatocytes leading to multifocal hepatocellular carcinoma displaying characteristic similar to that observed in human hepatocellular carcinoma. After 24 weeks, the number of liver tumors in Pgc1a À/À mice was reduced by approximately 60% compared with Pgc1a þ/þ mice (Fig. 2B ). After 40
weeks following diethylnitrosamine treatment, we were not
Therefore, we examined mice for tumor burden. We observed a significant decrease in tumor burden in the livers of Pgc1a À/À mice compared with Pgc1a þ/þ mice 40 weeks following diethylnitrosamine treatment (Fig. 2C, right) . These data show that despite the reduction in oxidative phosphorylation and TCA cycle gene expression in Pgc1a knockout mice, loss of PGC1a protects against carcinogenesis.
PGC1a promotes tumor growth in vivo
Pgc1a whole body knockout mice exhibit multiple metabolic abnormalities (20) . In addition, given the ability of PGC1a to control the expression of metabolic genes, it may be altering the metabolism of the carcinogens used. Therefore, we wanted to determine the effect of PGC1a in a more defined setting. We reduced the expression of PGC1a in the Colo205 human colorectal cancer cell line using a lentiviral-based shRNA against PGC1a (Supplementary Fig. S1C ). Knockdown of PGC1a led to a reduction in oxidative phosphorylation and PGC1b gene expression ( Fig. 3A and Supplementary Fig. S1D ). Interestingly, despite the decrease in mitochondrial gene expression, we did not observe a difference in cell proliferation in vitro (Fig. 3B) . Because PGC1a plays a major role in nutrient sensing and homeostasis, we examined the effect of loss of PGC1a on tumor growth in vivo. We inoculated Colo205 cells expressing nontargeting-shRNA or PGC1a-shRNA into the flank of SCID mice and measured tumor xenograft growth. Growth of PGC1a-shRNA expressing cells was reduced almost 60% compared with control nontargeting-shRNA expressing cells (Fig. 3C) . Next, we wanted to determine whether PGC1 could promote tumor growth by overexpressing PGC1a in the HT29 colon cancer cell line (which expresses little PGC1a; Supplementary Fig. S1E ). Ectopic expression of PGC1a increased the expression of genes driving oxidative phosphorylation (Fig. 3D) . In addition, we observe that PGC1a promotes the expression of PGC1b (Supplementary Fig. S1F ). Similar to the knockdown data, altering PGC1a expression did not appear to alter cell proliferation in vitro (Fig. 3E) . We then examined the effect of PGC1a expression on tumor growth in vivo. Control and Pgc1a expressing HT29 cells were inoculated into the flank of SCID mice, and tumor growth was measured. As shown in Fig. 3F , PGC1a-overexpressing tumors grew almost 3 times as large as control tumors. Although PGC1a did alter cell growth in vitro, these studies show a direct role for PGC1a in promoting tumor growth in vivo.
PGC1a promotes the expression of genes driving de novo fatty acid synthesis
Recent studies have shown that despite the well-known role of Pgc1a in driving oxidative metabolism, it can also promote de novo fatty acid synthesis (9, 10) . Lipogenesis has become recognized as playing an important role in tumorigenesis and cancer cell growth (2) . Indeed, the key proteins controlling fatty acid synthesis from acetyl-coA, acetyl-Co carboxylase (ACC) and fatty acid synthase (FASN), play an important role in promoting cancer growth (27, 28) . As shown in Fig. 4A , the gene expression of Acc and Fasn were reduced in the colons of Pgc1a À/À mice compared with Pgc1a þ/þ mice. Similarly, the expression of Acc and Fasn was also reduced in the livers of Pgc1a À/À mice compared with Pgc1a þ/þ mice (Fig. 4B) . We then examined lipogenic gene expression from the tumor xenografts with loss and gain of PGC1a expression. Knockdown of PGC1a in Colo205 tumors led to significant reduction in expression of both ACC and FASN (Fig. 4C) . Conversely, expression of PGC1a in HT29 tumors increased ACC and FASN expression (Fig. 4D) .
The induction of the TCA cycle and oxidative phosphorylation by PGC1 raises the question as to how these pathways are linked to fatty acid synthesis. Acetyl-CoA is required for de novo fatty acid synthesis from glucose. However, acetyl-CoA Ã , P < 0.05. B, PGC1a knockdown does not alter cell growth in vitro. Nontargeting-shRNA and PGC1a-shRNA cells were plated and counted every 2 days as described in Materials and Methods. n ¼ 3 AE SD. C, Knockdown of PGC1a reduces growth of Colo205 tumors compared with control nontargetingshRNA Colo205 tumors. Cells were inoculated into the flank of mice and tumor growth measured. n ¼ 8-10 AE SD. Ã , P < 0.05. D, overexpression of PGC1a in HT29 cells increases mitochondrial gene expression. RNA was isolated from pcDNA control and PGC1a-overexpressing HT29 cells. RT-PCR was carried out for the ATPsynF1 and Cyt c and values normalized to actin. n ¼ 3 AE SD. Ã , P < 0.05. E, ectopic expression of PGC1a does not alter cell growth in vitro. Control and PGC1a-expressing cells were plated and counted every 2 days as described in Materials and Methods. n ¼ 3 AE SD. F, ectopic expression of PGC1a increases the growth of HT29 tumors compared with control pCDNA HT29 tumors. Cells were inoculated into the flank of mice and tumor growth measured. n ¼ 8-12 AE standard error.
produced from glucose is generated in the mitochondria, whereas fatty acid synthesis occurs in the cytoplasm. To use acetyl-CoA for fatty acid synthesis, it is converted to citrate in the TCA cycle and shuttled out of the mitochondria by the mitochondrial citrate transporter, solute carrier family 25, member 1 (SLC25A1). In the cytoplasm, ATP citrate lyase (ACLY) converts the mitochondria-produced citrate into oxaloacetate and acetyl-CoA. Loss of PGC1a expression in PGC1a À/À mice or knockdown of PGC1 in Colo205 cells led to a reduction in SLC25A1 and ACLY (Fig. 5A-C) . In contrast, the expression of SLC25A1 and ACLY was increased in HT29 tumors overexpressing PGC1a (Fig. 5D ). Together, these data suggest that PGC1a coordinately regulates gene expression promoting metabolic pathways required for converting glucose into fatty acids. SREBP1 is one of the most well-studied transcription factors driving the lipogenic gene expression program in the liver (29) . A number of studies show that SREBP1c and its ability to promote lipogenesis play a role in increased tumor development and growth (30) . SREPB1c exists as a precursor in the cytoplasm and is activated by cleavage and subsequent nuclear localization of the mature form (2, 29) . This prompted us to examine the livers and colons of wild-type and knockout mice for the expression of mature SREPB1c. Loss of PGC1a did not alter the expression of cleaved SREBP1c in the liver and colons from mice ( Supplementary Fig. S2A and S2B ). In addition, we did not detect SREBP1c protein expression in HT29 and Colo205 xenografts (data not shown). This further suggests that PGC1a does not mediate its effects by regulating mature SREBP1c expression.
PGC1a directs programs of gene expression by interacting with transcription factors. One of the most well-characterized transcription factors mediating the effects of PGC1a on energy metabolism is ERRa (31, 32) . Interestingly, ERRa has also been shown to promote tumor growth and is associated with reduced survival in several cancers (33) (34) (35) (36) (37) . We examined the effect of ERRa inhibition in the liver of wild-type C57Bl/6J using an ERRa inverse agonist, XCT790. Inhibition of ERRa decreased the expression of cytochrome c expression, a typical target of PGC1a and ERRa (Supplementary Fig. S2A ). However, we did not observe a difference in SLC25A1, ACLY, ACC, and FASN gene expression following treatment with the ERRa antagonist ( Supplementary Fig. S2B-S2E ). While ERRa may be responsible for the effects of PGC1a on gene expression driving cellular bioenergetics, the data suggest that ERRa is not responsible for the effects of PGC1a on lipogenic gene expression.
PGC1a promotes lipogenesis
Given the ability of PGC1a to promote lipogenic gene expression, we next examined whether PGC1 promoted lipid accumulation. Initially, we examined TAG levels in Pgc1a Fig. S4A ). In HT29 tumors expressing Pgc1a, TAG levels were significantly increased ( Supplementary  Fig. S4B ). Measuring TAG levels shows mainly the steady-state accumulation of lipids and is not a direct measure of synthesis. Therefore, we used stable 13 C isotope tracer studies to determine the effect of PGC1a on de novo fatty acid synthesis. Mice with control or PGC1a-expressing xenografts were established and administered 13 C glucose, and plasma and tumors were harvested 3 hours later. Plasma from mice bearing PGC1-expressing tumors showed increased 13 CO 2 concentration (Fig.  6A) . This shows the increased glucose utilization in mice with PGC1a-expressing tumors even over the course of a short incubation time (3 hours). We then directly examined fatty acid synthesis in tumors by measuring the incorporation of 13 C Figure 4 . from glucose into palmitate, the product of FASN. Despite the short incubation, approximately 2% of the palmitate derived from tumors was 13 C labeled. This increased by more than 15% in the Pgc1a-expressing tumors (Fig. 6B) . We also examined plasma 13 C-labeled palmitate to determine whether the labeled palmitate was derived from nontumor tissue and subsequently taken up by tumors. The percentage of 13 C-labeled palmitate in plasma was much less than 1% of the total palmitate and did not change in plasma from mice bearing PGC1a-expressing tumors, confirming that palmitate was being produced by tumor ( Supplementary Fig. S4C ). Subsequent positional mass isotope analysis showed that the increase in labeled palmitate was due to increased de novo synthesis, which was increased more than 50% compared with control tumors (Fig. 6C ). RNA was isolated from tissue and RT-PCR was carried out for SLC25A1 and ACLY as described in Materials and Methods. n ¼ 8-12 AE standard error. Ã , P < 0.05; ÃÃ , P < 0.01. WT, wild-type; KO, knockout; NT, nontargeting. Figure 6 . PGC1a promotes tumor growth by increasing de novo fatty acid synthesis. A, PGC1a increases 13 CO 2 production from glucose. B, PGC1 increases incorporation of glucose into palmitate. C, PGC1a promotes de novo palmitate synthesis. Mice with vector control or PGC1-expressing tumor xenografts were administered [U6- 13 C 6 ] glucose for 3 hours, plasma and tumor tissue harvested, and stable isotope analysis conducted as described in Materials and Methods. D, inhibiting fatty acid synthesis blocks the effect of PGC1 on tumor growth. HT9 control and PGC1a-expressing xenografts were established in SCID mice. Once tumor formation was detected, mice were treated with 10 mg/kg C75 and tumors measured for the indicated time. n ¼ 5 AE SD,
PGC1a-mediated induction of fatty acid synthesis promotes tumor growth
These studies show that Pgc1a expression is associated with induction of a program of lipogenic gene expression and de novo lipogenesis. However, it does not show that increased fatty acid synthesis per se is mediating the effects of Pgc1a on tumor growth. To test this, we established pcDNA control and PGC1a-expressing xenografts in mice and inhibited fatty acid synthesis with the FASN inhibitor C75, once tumors had formed (38) . We used a lower dose of C75 than previous studies, given the ability of C75 to inhibit tumor growth. Similar to the studies above, Pgc1a-expressing tumors grew about 3 times as large as control tumors (Fig. 6D) . C75 reduced the growth of the control tumors at about 20%, although it was not statistically significant. In contrast, C75 treatment of mice with tumors expressing PGC1a significantly reduced the growth of tumors by approximately 50%. This shows that the tumor growth promoted by PGC1 is mediated, in part, via induction of fatty acid synthesis.
Discussion
Altered cancer metabolism has become recognized as a hallmark of cancer. Although the Warburg effect and glycolysis are recognized as key aspects of tumor metabolism, tumors cells need to be able to coordinate energy-generating and biosynthetic pathways to effectively promote cell proliferation (2-4). PGC1a is a key metabolic regulator that controls multiple aspects of glucose metabolism. Our studies show a novel role for PGC1a in promoting carcinogenesis and tumor growth. This effect appears to be mediated via coordinating the induction of a gene expression program that facilitates the conversion of glucose to fatty acids.
Elevated fatty acid synthesis has become recognized as an important pathway in cancer (2) . In addition to generating membranes for biomass, lipids are used for signaling pathways that are often elevated in many cancers. Lipids play an important role in transmitting signals from the plasma membrane via second lipid messengers and eicosanoids. In addition, lipid modification of a number of oncogenes, including RAS and AKT, is required for full oncogenic activation (39, 40) . Therefore, the ability of PGC1a to modulate fatty acid synthesis would also provide cancer cells with precursors for signal transduction pathways regulating cell growth.
Although increased mitochondrial function in terms of the TCA cycle and oxidative phosphorylation are typically associated with reduced growth, recent studies highlight the need for oxidative phosphorylation and the TCA cycle in promoting tumor growth (14) (15) (16) . Indeed, several studies show a potential role for PGC1a in this process. Ectopic expression of KRAS in NIH3T3 fibroblasts leads to increased proliferation, which is associated with increased PGC1a and its downstream target genes (17) . The ability of breast cancer cells to metastasize to the brains of mice was also associated with increased PGC1a expression and its target genes (18) . Another study showed that activation of PPARd induced cell proliferation, which was associated with increased PGC1a expression (41) . Despite the association between PGC1a and cell growth, a direct role for PGC1a was not shown. A more recent report showed that knockdown of PGC1a in prostate cancer cells reduced growth in vitro (42) . However, the prostate cell lines used have very little PGC1a, raising questions about PGC1a knockdown.
These studies highlight the observation that multiple metabolic pathways regulate tumor cell growth and that increased mitochondrial function per se does not necessarily inhibit growth. The coordinated induction of TCA cycle and oxidative phosphorylation by PGC1a would provide cells with a strong metabolic advantage. Making a daughter cell is a bioenergetically costly endeavor whereby glucose is used for both energy and biosynthetic precursors. Induction of oxidative phosphorylation and the TCA cycle by PGC1a would enable cells to make more glucose available for biomass generation, as oxidative phosphorylation and the TCA cycle are more efficient at generating energy. The importance of lipogenesis in tumor metabolism highlights another need for the induction of the TCA cycle by PGC1a. De novo fatty acid synthesis from glucose requires acetyl-CoA. However, acetyl-CoA is produced in the mitochondria, whereas fatty acid synthesis occurs in the cytosol. Therefore, the TCA cycle is required for converting mitochondria-generated acetyl-CoA into citrate. Our studies show that PGC1a plays an additional role in this process by (directly or indirectly) inducing the expression of genes involved in these pathways and bridging the known mitochondrial and lipogenic functions of PGC1a. ACLY promotes the conversion of citrate back to oxaloacetate and acetyl-CoA, providing substrates for fatty acid synthesis by ACC and FASN. Therefore, our studies suggest that PGC1 is coordinating energy production and mitochondrial function with biosynthetic pathways to fuel cancer growth (Fig. 7) .
The ability of PGC1 to regulate energy metabolism occurs, in part, via coactivation of the transcription factor ERRa (31, 32) . Recent studies highlight an important role for ERRa in promoting cancer growth in several different cancer types (35, 36, 43) . It has also been reported that higher expression of ERRa is associated with a worse prognosis for several cancers (33, 34, 37) . A stronger connection between ERRa and PGC1a was suggested in a recent study which showed that tumorigenesis of fibroblasts by KRAS is mediated, in part, by PGC1a and ERRa (44) . However, using an inverse agonist of ERRa, we did not observe an alteration to lipogenic gene expression in livers of mice. Therefore, although PGC1a might regulate the expression of genes driving energy metabolism, it most likely regulates lipogenic gene expression independently of ERRa. In contrast to ERRa, SREBP1c is a key transcription factor mediating the program of lipogenesis. We did not observe a difference in expression of mature SREBP1c in livers or colons of Pgc1a À/À mice. Further ruling out a role for SREBP1c was the lack of SREBP1c in the Colo205 and HT29 xenografts. However, the possibility exists that PGC1a may be interacting and coactivating SREBP1c to increase lipogenic gene expression without altering the expression of SREBP1c. Future studies will elucidate the mechanism(s) by which PGC1a promotes lipogenesis in cancer and whether the ability of PGC1a to promote gene expression programs regulating energy metabolism and lipogenesis is the result of distinct or related transcriptional programs. In addition, it remains to be determined whether the effect of PGC1a on SLC25A1 and ACLY expression is a direct transcriptional effect or whether it is secondary to induction of fatty acid synthesis. The gain and loss of PGC1a expression studies presented here help to resolve the conflicting data about the role of PGC1 in cancer. However, a recent study overexpressing PGC1a in a breast cancer-derived xenograft model did not observe a difference in growth in control tumors versus tumors expressing PGC1a (45). Because we observed an effect of PGC1a on tumor growth using both gain and loss of PGC1a expression in colon cancer cell lines, tissuespecific differences may explain the contradictory results. Indeed, recent studies suggest that PGC1a displays tissuespecific differences in function (46) . Hence, PGC1a may be a target in colorectal and liver cancer but not breast cancer.
Despite alterations in oxidative metabolism gene expression in vitro, we primarily observed an effect of PGC1a on tumor growth in vivo. The difference between in vitro and in vivo effects may be explained by the important role that PGC1a plays in nutrient response and signaling. In cell culture, most nutrients, such as glucose and oxygen, are not limiting. However, in vivo, the tumor microenvironment is an area of intense metabolic stress where nutrients are more limiting and therefore PGC1a may play a more important role. Our in vitro data also disagree with a study showing that knocking down PGC1a in prostate-derived cancer cells reduces growth in vitro (42) . In addition to questions about expression of PGC1a in prostate as mentioned above because PGC1a is primarily a transcriptional coactivator, these differences may be attributable to the presence of cofactors that are expressed in a tissue-or cell type-specific manner. A recent article described an antigrowth role for PGC1a in the colon (26) . It is unclear as to the reasons for the contradictory result. Our studies used stable Lentiviraland retroviral-based technologies, whereas the recent study used adenoviral PGC1a injections directly into tumors. In addition, D'Errico and colleagues found that loss of PGC1 protects against tumor formation. Possible differences may be attributed to the chemical and genetic models used and strain differences. In addition, a question that is raised in general with regard to the studies by D'Errico and colleagues is that they show that PGC1 prevents tumorigenesis by promoting ROS. However, studies show that PGC1a protects against generation of reactive oxygen species and upregulates antioxidant defense (47, 48) .
Previous studies show that PGC1a is reduced in tumors (12, 13, 18) . Most of these studies primarily show an association between PGC1a expression and tumor growth and did not directly determine the role of PGC1a on cell growth. Therefore, PGC1a may play a role during carcinogenesis and then its expression decreases as tumors develop. Indeed, our data suggest that PGC1a represents a potential therapeutic target for chemoprevention. Obesity and diabetes are independent risk factors for developing liver and colon cancer (49, 50) . Importantly, a number of studies show that PGC1a expression is elevated in the livers of obese/diabetic mice and patients. We also observe an increase of PGC1a in the colons of obese mice with type II diabetes (data not shown). Obese and diabetic individuals can be readily identified and therefore suggests that in these identifiable at-risk patients, targeting PGC1a may be a useful cancer prevention strategy. In addition, although our data point toward PGC1a playing a role in the early stages of cancer, our data using established cancer cell lines suggest that the presence of PGC1a is sufficient to promote tumor growth. Therefore, notwithstanding the reduced expression of PGC1 in established tumors, PGC1a may be a therapeutic target in tumors where it is present.
Most studies showing that metabolism is altered in cancer have been done in established cancers. Therefore, the role of metabolism on carcinogenesis is less well defined. These studies provide support for metabolism and its regulation by PGC1a as an important component of tumorigenesis and tumor growth. Importantly, PGC1 appears to accomplish this via inducing the expression of a gene expression program that coordinates the conversion of glucose into fatty acids. In conclusion, these studies suggest that reducing PGC1 expression/activity represents a potential therapeutic approach for targeting multiple aspects of altered cancer metabolism.
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